Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January

December 28, 2017 By Law Offices of Thomas J. Lamb, P.A.


Approval

On December 19, 2017, the FDA approved Merck & Co. and Pfizer’s new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet.  These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January.

Steglatro consists of ertugliflozin, while Steglujan combines it with Januvia (sitagliptin), and Segluromet combines it with metformin.

According to the drug label (for Steglatro, accessed 12/28/17), these drugs are “indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.”

A recent MedScape article provides the following information:

The new drug applications were accepted for review in March 2017 and were supported by studies from the VERTIS clinical development program for ertugliflozin, which consists of nine phase 3 trials in approximately 12,600 adults with type 2 diabetes.

Results from VERTIS MONO, VERTIS FACTORIAL, and VERTIS SITA2 were presented at medical congresses in 2016, and findings from VERTIS SU and VERTIS SITA2 were presented at the European Association for the Study of Diabetes (EASD) 2017 Annual Meeting in September 2017.

 

New Drug, Same Side Effects

Like other SGLT2 inhibitors — such as Invokana, Farxiga, Jardiance, Synjardy, Glyxambi, and Qtern — these new type 2 diabetes drugs also carry warnings of the following serious side effects:

  • Ketoacidosis
  • Acute Kidney Injury
  • Impairment in Renal Function

There is also a lower-limb amputation warning for Steglatro and its counterparts.  This is particularly interesting, given that Invokana is the only other SGLT2 inhibitor at this time whose drug label also mentions this warning.

However, unlike Invokana, Steglatro (and its combinations) do not include amputations in a so-called “Black Box” warning.  This is probably due to the label’s claim that “A causal association between STEGLATRO and lower limb amputation has not been definitively established.”

Perhaps the drug companies responsible for Steglatro, Steglujan, and Segluromet added this warning so as to protect themselves from lawsuits in the event that a causal relationship between these drugs and lower-limb amputations is definitively established in the future.

 

Class Effects

While other SGLT2 inhibitors are quick to distance themselves from the lower-limb amputation side effect, further clinical data may prove it to be a class effect.

The first three side effects mentioned above have been shown to apply to the entire class of SGLT2 inhibitors diabetes drugs, and as such, are mentioned in every single drug label for these drugs.

We will continue to monitor the medical literature on SGLT2 inhibitors and their relationship to lower-limb amputations and other serious side effects.  In the meantime, we encourage you to visit our website and complete a free case evaluation if you or someone you know has taken an SGLT2 inhibitor and suffered one of the serious side effects mentioned in this article.

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.

 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: diabetes drugs side effects, drug safety news, Farxiga, Glyxambi, Invokamet, Invokana, Jardiance, merck, new sglt2 inhibitors diabetes drugs, pfizer, Qtern, Segluromet, sglt2 inhibitors diabetes drugs, Steglatro, Steglujan, Synjardy, type 2 diabetes drugs, Xigduo

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.